

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):	Richard S. Bein	EXAMINER:	Jagadishwar Rao Samala
SERIAL NO.:	10/796,604	GROUP:	Art Unit 1618
FILING OR 371(C) DATE:	March 8, 2004	DATED:	July 7, 2011
TITLE:	COMPOSITIONS FOR USE IN EMBOLIZING BLOOD VESSELS COMPRISING HIGH LEVELS OF CONTRAST AGENT		
Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	<i>Filed Via EFS-Web</i> <u>Confirmation No.: 1765</u>		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to Applicant(s) duty of disclosure, the information listed in the attached form PTO/SB/08A is brought to the attention of the Examiner. Copies of the U.S. patent documents are not provided in accordance with the waiver of that requirement under 37 C.F.R. §1.98.

The documents provided are a Canadian Office Action just received in the Canadian application corresponding to the above-referenced application, and the Written Opinion of the International Searching Authority for the PCT Application, which the Canadian Office Action relied upon and included as part of the Office Action.

The citation of the listed items is not a representation that they constitute a complete or exhaustive listing of the relevant art or that the references are prior art. The items listed are submitted in good faith, but are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner of these particular items, they will assist in identifying fields of search and in making as full and complete a search as possible.

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being transmitted on the date below with the United States Patent and Trademark Office, PO Box 1450, Alexandria, VA 22313-1450, via electronic submission.

Dated: July 7, 2011


Nicole Risponde

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Applicant(s) hereby state(s) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than 3 months prior to the filing of this statement as set forth in 37 C.F.R. §1.97(e)(1).

Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or 1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account **50-5388**. Also, in the event any extensions of time for responding are required for the pending application(s), please treat this paper as a petition to extend the time as required and charge Deposit Account No. **50-5388** therefor.

The claims in the present application are believed to be patentable over the prior art and are in condition for allowance. Early and favorable consideration of the case is respectfully requested.

Respectfully submitted,



Michael R. Brew
Reg. No.: 43,513
Attorney for Applicant(s)

Carter, DeLuca, Farrell & Schmidt, LLP
445 Broad Hollow Road - Suite 420
Melville, New York 11747
Tel.: (631) 501-5700
Fax: (631) 501-3526
MRB/nr